Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Growth in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 18,900 shares, an increase of 90.9% from the March 15th total of 9,900 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is currently 2.3 days.

Institutional Trading of Aethlon Medical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in shares of Aethlon Medical by 11.6% during the 1st quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock valued at $395,000 after purchasing an additional 28,097 shares during the last quarter. Two Sigma Investments LP purchased a new position in Aethlon Medical in the 3rd quarter worth $32,000. HRT Financial LP purchased a new position in Aethlon Medical in the 4th quarter worth $28,000. Citadel Advisors LLC purchased a new position in Aethlon Medical in the 3rd quarter worth $72,000. Finally, Jane Street Group LLC raised its stake in Aethlon Medical by 895.7% in the 4th quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 126,160 shares during the last quarter. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Trading Down 1.0 %

Shares of AEMD opened at $1.64 on Thursday. Aethlon Medical has a 12 month low of $1.40 and a 12 month high of $7.20. The stock has a fifty day moving average price of $1.71 and a 200-day moving average price of $1.80. The firm has a market cap of $4.30 million, a PE ratio of -0.33 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.14). As a group, research analysts forecast that Aethlon Medical will post -4.98 EPS for the current year.

Analyst Ratings Changes

AEMD has been the subject of a number of analyst reports. HC Wainwright lowered their target price on Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a report on Monday, March 4th. StockNews.com started coverage on Aethlon Medical in a report on Thursday, April 4th. They set a “sell” rating for the company.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.